SUPN - Earnings call transcript Q3 2020 | Supernus Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Supernus Pharmaceuticals Third Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Peter Vozzo of Westwicke, Investor Relations representative of Supernus Pharmaceuticals.

You may begin.

Peter Vozzo

Jimmy. you, Thank and Supernus everyone call. for us joining Good third thank quarter for Pharmaceuticals' conference XXXX today morning, you financial results Yesterday, results. the press after of company the a issued market, release the these announcing close

section Officer, the On the today retiring the has Chief call me of Jim call and who being Investor our Officer, Patrick, available announced, Chief is Jack Financial Kelly. at Chief Greg Officer, website are Financial previously ir.supernus.com. Khattar; Supernus' with Relations Executive via is newly made company's appointed Today's

Following call remarks open by management, we to will the questions.

uncertainties, management During forward-looking make These the course statements are on existing of this and perspective future current forward-looking call, events differ regarding performance not noted performance. the statements. trends Supernus' company's these those may future company's and XXXX such statements forward-looking Any guarantees and reflect those Risk statements section forward-looking XX-K. and certain Form materially may information. on risks involve Actual of including Factors future results from Annual the the in in of projected Report

the Please laws. securities call obligation AM update applicable made these to now For recent Time. discussed. press except of X, may the the any to declines required to releases will XXXX reference listening by on over most topics is you approximately and the this company's turn with the additional forward-looking the Supernus and current Jack. SEC. filings I call at announcements X:XX as those the related be replay, being then, November have who Since held of company benefit may recorded Eastern to statements

Jack Khattar

pandemic. to Supernus and our we the significant everyone, this has XXXX challenges year, the Peter. time third Good Thank thanks as for COVID results. by morning, discuss caused taking continued progress despite made quarter us you, join the

months base its XXXX, long-term Supernus During performance, enhanced nine the and strong prospects. product revenue sales first delivered its of diversified growth

integration of integration advanced continue transactions company and The late-stage has been progressing completed activities products be on well, its two by pipeline. the significantly the executed expect Parkinson's corporate to addition, we all and disease In to year-end.

the starting we pipeline submitted and of XXXX FDA, And late-stage target date for by product to the with review, approved in to the a SPN-XXX September engaged fourth the Infusion if launch NDA, quarter our this Pump with of Regarding negotiations. SPN-XXX, action the including their of plan regarding the year. with NDA we we or in X, Turning PDUFA Apomorphine FDA the remain XXXX label November ongoing

sales are U.S. the track more environment. Our XXXX. we sales total ADHD us audience We of the launch. by plan physician in preparation of digital and SPN-XXX on and the promoting is salesforce, segment, in readiness our salesforce enrollment to from help use SPN-XXX of half Phase to in and and We've the effectively XXXX adult total SPN-XXX of with an implemented XXX approximately as SPN-XXX various expect if having for top the representatives, then XXX FDA the in the a will trial And by needed allow of all sales our represents January, launch team completed platforms management for than our COVID in launch to approximately patients commercial reps neurology the expertise quarter has line transporting expand of IIII reach and the internal commercial our the adult products XXXX. This approved which data in to representatives market first us restrictive the current important our the the goal market backfill leveraging with neurology current virtual

XXXX. resistant activities Activator, depression a preclinical program the Phase end II orally of goal our are SPN-XXX, first-in-class clinical treatment active of initiating ongoing regarding mTORCX and and Finally, development by with the

commercial the onto products. Moving

Overall, are overall performance on and the adverse year access patient with of patient of We impact initiations. nine the despite of Oxtellar IMS visits, by at represented the to new the physicians, pandemic our the growth salesforce, same to looking products, the units first and resiliency pleased period X% showed prescriptions strong XR tablets compared total, the a extended for reported with in last the year. number months as showed growth by as of XX%

period strand units size by the while due first Trokendi larger the IMS monthly upwards approximately of since to for is prescription units last of the XR the trending third declined and XR been prescription average X% sustained a through For XXXX the This of declined XR compared monthly prescriptions of quarter. extended that in the such for size extended pandemic has start nine XX%, by the Trokendi to and fact months was Oxtellar year.

in product increasing In environment we been other well, in by year. third with growth year the acquisition than the of most MYOBLOC that to initiation continues sales pleased seen pandemic. and patient with the with and uncertain of has product the expected summary, couple first Oxtellar and physician together sales and in this with we're has expectations on instrumental in effected visits of and for the are per XXXX net operating this impact of annual overall Similarly, average XR better sales resulted where to in despite Parkinson's Taken performing deductions this pandemic products. portfolio the in hand resulted we a price have originally And to compared gross Trokendi therapy in full that the and therefore, APOKYN cost all are the last higher we been in increase, the quarters, net both months be XR second for prescription when our the performance XX% XXXX you wholesale maintenance. XADAGO of nine the and earnings. performance favorability

our continue we and growth be leadership strengthen to in in further opportunities strategic for to active CNS. Finally, position looking future

you of forward. leadership, like and discipline, and contributions course, I you to know to for moving to financial dedicated progress thank background, our And, many would our and Jim Officer. of role. Jim's financial updating quarter Greg the to financial like accomplishments, on I experience team new on of his welcome nearly I of years as third the now makes Before call that, looks established our in public a would as to know Financial well Greg more Greg to as and performance, including he I to company turn With a Supernus track I'll the foundation. built him. transition. getting provide for call his hand experience XX a Chief years suited company has Supernus commitment smooth to CFO record the over forward to details solid him numerous to on over our industry and well-prepared Kelly strong

Gregory Patrick

Thank everyone. and morning, you, Jack good

XXXX products volume results, in million of same to from was quarter of I January of the third refer of in product products for and press As disease the million, and review increase sales revenue expansion million. due an third product was taken release. and of $XXX.X XXXX $XX.X X% the yesterday's Total of Trokendi our of please $XXX.X over third revenue XX% sales period Oxtellar XX% net million royalty In revenue price compared Oxtellar the XXXX $X XR increase Oxtellar year. and to XR. the Parkinson's comprised for an Trokendi XR both increased for $XXX.X to XR same net in last quarter Total quarter quarter million, XR

to of essentially same expenses $XX.X from in million last third to were quarter primarily Turning This the were due for XXXX, year. million quarter $XX.X third and year second expenses Research the prior $XX.X the expenses disease development $XX.X Parkinson's unchanged this expenses. year. in the of period. $XX.X million for to quarter of XXXX million increase products million next compared was SG&A in associated the with the quarter the acquired

year-over-year increase. preparations contributed to for of the In our expense launch addition, ongoing SPN-XXX the

million share earnings the $XX.X compared $X.XX million million million result in period a quarter XXXX second Net quarter year. year. same compared assets of share of same expense WorldMeds the were diluted XXXX last earnings or to the of quarter or quarter quarter the US year. amortization was of quarter were the million $X.XX the As to in million in $X.X for last XXXX last third year, third to $XX.X this third the for Operating $XX.X diluted per in $XX the in intangible acquisition for third per $X.X compared

marketable XX, XXXX. December As of had million cash, equivalents, $XXX cash of marketable in company long-term and securities as XXXX, securities, the September XX, million $XXX to compared

acquired During cash nine this Navitor option the for $XXX months generated plus the inflow, the products, first related the SPN-XXX. cash expenses, $XX of disease payments Offsetting XXXX, to inclusive upfront the Parkinson's million of agreement company development and $XXX executing of million for upon operations. million from made of approximately acquisition company cash

Supernus at company to appreciation would the as years. Before my to investors, past the over turning colleagues I to nine Directors my to our to the opportunity like for well call the Jim, our Board of as you, express and Thank you. serve

James Kelly

and hey. the will Greg, an especially I at an Thank Supernus. nine greatly incredibly know amazing years last All your you, congratulations miss career in right. team Well, on leadership. contribution impactful and

guidance. So, to financial turning now

reflects Parkinson's our for XXXX. operating year the expenses. the guidance financial guidance of guidance disease lowering product raising year Recall, are earnings, X, full acquisition updated while XXXX net We June as and for of this products sales SG&A full R&D and

the million. range as net $XXX million full full marketing to the the expect be million compared to the to market in million the SG&A expected of by call. R&D expenses expected previous build $XXX to to expected million quarter SG&A compared mentioned million the to to approximately product range $XX the expenses $XXX prepare increased to out the and previously Jack million compared to to approximately as to for from due spend of to SPN-XXX to fourth For at $XXX are from quarter, million. million million salesforce, to $XXX year $XXX expenses the we market sales launch million. of to $XXX are third previously year from range XXXX, the the expected earlier $XX XXXX from anticipated the range -- be $XX expectation higher are least on compared $XXX

assets. of amortization to Turning intangible

compared We year previous expect $XXX intangible to XXXX operating estimate anticipate million earnings the inclusive to assets. of We full $XX full incur range of for approximately from $XX year to the million million. amortization now to of $XXX

now to operator to your the we'll turn said, over that call with the take So, questions.

Operator

Cacciatore Instructions] Company. [Operator Our comes with and Ken you. first Cowen from Thank question

now is line open. Your

Ken Cacciatore

care the on Greg, been amazing elongated about what first, to think of and that going year, how managed January. timeframe with an we've in you. first, been launching before pacing? get It's Can kind your Jack, seeing lot My know season managed much. question We Thanks launches. push board the the we these really to is introduced great I out all run. in to just working fall, And go XXXs back-to-school you Congratulations be of the about launch. you're and we next best we care the a so should work And as on for going retirement. in product, on is talk

And -- you. approved, about Trokendi. thinking that investments? P&L how of So, we of to should little just question profitability if from just balancing now as Thank we be look And kind kind be that that's just hopefully exclusivity, bit how thinking for and Trokendi's late balancing end of apomorphine exclusivity ramp? versus balance the will is standpoint as in then XXXs around how how we a these product versus pump, a -- get launches of look the we we the maximize should second

Jack Khattar

morning, good Hi, Ken. Yeah.

far about elongated so period as accelerated and chatting working discussions XXX for of we've industry, forth coverage them. Regarding as with that the in seen the care and you and year the payers And, data that as recent our first, launches course, as a and so a Phase we accounts that started managed now. with III and those with mentioned half we far and been and we've got launch all managed key forth as the care

we've pretty of minimize have try delayed to been coverage period possible, lack So, soon coverage access as coverage. that speak, working to or of hard elongated, as and to so

the a good hard to sure to product working right can across that from get really are beginning. start, we off the board the do So, make

the you that season are be obviously, We ready to. also for school -- we'll refer

the that our in six would continue So, coverage to months improve. will first we expect

we season, the get said to to should we So, have to the if we expect we school ready full as January, launch the coverage so as we -- product launch, improve in be we overall. to that fully access continued assuming

profitability, Trokendi product. the for allocation how Regarding so XR great the question, exclusivity have Trokendi we forth? course, balance potential and still we still do two XR, years, we believe solid resources hopefully of and a there's Of for

has the it's still it a to the So, than to potential again, interaction product. by when tremendous you so competition. physicians hurt separate we're, did XR, the very year's patients. the to out genetics the obviously and the This had brand obviously chance support despite and pandemic from continue have face-to-face issues CGRPs Oxtellar don't because more your It's there before difficult brand sampling forth the with have and penetration with

So, the we that for will all year. next balance

future this And driver not company. course, our company. the future Trokendi of Of a priorities growth are for XR is in drivers our

for see So, the naturally that asset, pump. us portfolio by believe asset resource promising by us which followed behind the the in the of company you up SPN-XXX Hopefully, will a next we end we end the of if doing is lot launching most as year. great and allocation specifically a assets

two as two launches we're And both we clearly, of whole looking months, will a at invest future. for products them. the for Supernus XX theoretically, appropriately So, at behind in promise great product

While that in very to time on, data. future advance at as that a more of be more exciting hope XXX, we'll goes to is exciting we share and continue same which time, the the asset able

Ken Cacciatore

you. Thank

Operator

Thank you.

Our comes next from Jefferies. Steinberg with question David

now is Your open. line

David Steinberg

questions. A much. of couple very Thanks

you technical on you're there quarters? the far -- change quarter, then getting can to the potential prior you Trokendi any did two give guidance, of pear versus question. some you And First And December pretty you're sales approval research any be co-pay net with assistance? as January, going your changes on stocking of just the to goes, stocking? update in more just for XXX in gross in there us close was as the XR, And updates but any of share in know then launch. a will any launch us Jack, I done. you've can the to from and XXX Thanks.

Jack Khattar

Yeah. Sure.

we didn't -- The see stocking. Trokendi anything really on first question regarding any XR,

in we've net gross gross there is the normally normal the gross the -- is one year. to co-pays, the we in to net in seen quarter know ugliest you gross improvement see in the every with and other as to what things over to is first which the quarter, quarter year, net, then far what which or from third after As or net general, typically to improve all slight

and specifically saw, exactly improvement. So, third the we during quarter, year the in regular continue, the that's the what

that which expect a was adjustment did to Now, a emphasize the recall you quarter. we might last gross didn't had it repeat. to net, last quarter, we one-time That we to one-time thing

not repeat as favorable did it to the in third adjustment gross the a for So, net quarter.

improvement as on. So, any year improvement the in the third the quarter was of first time goes your versus the typical quarter

possible first It's to XXX talked introduced, As mentioned to my we comments, mean, all chemical and the as in I broad a a about meaning have III, profile far action. as the possible in with Phase as well in the in continue the far anything is action, works disease forth, differentiated seen to very unique is we've that more product FDA anything coverage it research approved as far the efficacy, mean, by onset a in as its than and we early new different is hard the category, Intuniv this new spectrum It's hyperactivity attention. entity. since as we molecules and mechanisms introduced as It's really state, that earlier of decade. working if as of differentiated. very research are mechanism shown it's access and conversations product, striving in of different had we equally and a point tolerability, I payers and of Vyvanse in XXX same and action. so have very a type XXX as And very, that haven't much payer this as clearly. as I hopefully

have when totality look So, profile, III our don't data, a clearly the you at the label Phase based on yet. of again, we

the our versus us at XX in proper the reformulations have program not nothing, they've KOLs, a seen and the Phase me data We the and as III talking have years, comments. of see don't so, with last But it's payers, XX We product. seen methylphenidate. we've sharing years any look it really this data have So, regarding this shown or make for or they what They and to with or excitement approval. I'm don't label. our but amphetamines data in

-- about it anything December, continue product out but any to we should anything expect marketplace. be might something for there. excited a ship So, end it if sales in meaningful. specifically be the mean, treatment up think any and we extremely option the we differentiation its patients there in in And is won't Do December? I become we an being major

year for or So, an sales. much our this guidance XXX really reflect of doesn't

David Steinberg

Thanks.

Operator

you. Thank

with Our Annabel One next Samimy question Stifel. comes from moment.

Your line is now open.

Annabel Samimy

Greg, taking on questions. my your bit a for Thanks Hi. retirement. all jealous. little congratulations And We're

here. a questions few just So,

resonate about any the of label here WorldMeds that in that you in some Now rates, products? compliance should can any there there? anything what discussions. any population uptake? in around with game prescribers, And to there are you areas late and us in penetrate have I'm optimize the APOKYN can like had about really you quarter, terms Thanks. what with looking the for of thinking you've you're identified be on surprising of sales, to a we for give more And XXX, physicians What further? the you're very specifics growth can Is barriers points you labeling Are and other what sure and might do general? the refill

Jack Khattar

Yeah.

we A diligence talked no. Parkinson's when we since are one did the firstly, no pandemic that the surprises at speak about been also that Regarding over. the MYOBLOC, The moment, knew a the total the well, so major through products was the to times, APOKYN, negative took highest. obviously couple our the on and we which There that portfolio as side, transaction. due at its time about bad of given we has

on the of for doctors injection. So, brand visit their actually to and we far initiation what it of patients and that patients as well impact aware get as potential necessity given were the and MYOBLOC very the takes

overall, continue very we're APOKYN performance So, pleased the the the of well. circumstances. to perform with given products,

very it continued in Yes, to again, its some COVID you the the there impacted. patient within patient and general area, because Parkinson have compliance performance we the given new with believe environment, pleased the adversely -- challenges are So, are visits, with initiation, has been patients.

we're the stability has the actually despite brand the -- pleased and of brand showing not been However, growth very with stability. performing some how that even some just

So, we're APOKYN. very excited about

been far. any we midst the The discussions question on the of the and identified very the promoting have again, the close very of on on with promises very cannot I products product. pleased working well. the part the of acquired. specific, what don't salesforce But think impact comments with is performing opportunities pleased We're to with any the how team we're make that there, too in team way are the optimization we to we've are until optimize a can't any on tremendous where as we are the And the We but some about think don't all job really specific so side and few we've we overall, areas side, that label, these label, doing the we it. we I make could with products. commercial there potentially on done are be see really FDA. I a really given I want next be of the want we XXX

Annabel Samimy

are for are follow-up running Okay. could for running just on or cash? If that APOKYN, you I growth that you

Jack Khattar

pump for the brand more clearly, product to products. importantly, we the a working acquired we're has just at for level. get -- we and to because a hard rejuvenate growth. mean, is potential the products coming run not huge it The extremely and APOKYN every the And We of can next year. especially higher make I And that

the product, to as an basically pump pen, the potentially injection includes, pump, is together in That we to franchise, be grow pen the the the APOKYN our is having successful one as plan, apomorphine even also as grow franchises So, -- of well leading really plan franchise and a our the APOKYN maintain the which the course, launch but Parkinson's. injection. on of

Annabel Samimy

Okay. you. Great. Thank

Operator

you. Thank

of comes Amsellem question next from Piper Our David Sandler.

Your is open. line now

David Amsellem

Hey. Thanks.

couple on Just my a end.

the if your And which a have the is competitive what product, what's of I co-exist? is on your subcu on secondly where AbbVie can modality dynamics -- formulations and market the form on your one. That's Thanks. commentary or Do and apomorphine? apologize missed overall as XXX? the First, impact franchise? could love continuous APOKYN the And competition apomorphine the that thoughts think could but of co-exist, your there sense of usage do the pump, low thoughts and sublingual number that are pro-drug And to and Levodopa your that's this that the into the you multiple there. -- enough of on something I extent then, that you what for of think can franchise, there come infusion product, on the get to potential pump dynamics long-term

Jack Khattar

Starting the head-to-head all, about really and general and Sure. question point just trials. of to with apomorphine no And in first KYNMOBI. Yeah. your important are clinical there it's APOKYN

of APOKYN. that see patients early get it's with XX really only supported Phase not is XX strong -- That minutes. what you efficacy efficacy. relief fairly III mean, see reliable can very, the to not working as within -- is XX is robust. been comparison. that data can actually. behind I'm And the XX% our I APOKYN is within reliable, our specifically very with, So, minutes, has referring it's product see truly I mean, product fast as to data the our really the course, kind in also fair this And data, of and that and is what you you minutes of And talk really about efficacy, I a All amazing about, label, what starts

bed. mean, that somewhere first actually that the days robust sometimes If difficult dose of I the the the that they also off these a even something dose. Also patients. the first even time have or number resolved. from strong. I benefit efficacy. we around you of of of meaning less functionality, mean, this and It I XX% episodes have XX% important obviously dose they extremely that, of of take during out is when mean, XX% A efficacy maintaining to really addition that are to really know and this getting getting lot an it In efficacy, is data is in numbers this the you with dressed reliability very the day take about remember patients another or last through the product. here, but the XX% XX%. from robustness the is speaks I

sublingual injection very all very, in and an this feel we will efficacy that occupy strong can APOKYN the you APOKYN than Apomorphine tablet. That's data see, I very is product. label because the is about on the can of So, APOKYN. delivery the pen The very behind different KYNMOBI of behind drug a category, read good really But guys the strongly position profile. obviously. its in

may we So, both a we products. up with think for patient profile end very different

So, clearly actually this place Levodopa have realize a help question, I an therapy both next think the category, has understand marketplace. to, based a product that will in in which product. your us room which there not AbbVie apomorphine in based is a and and referred general against later more the And to drug is extra apomorphine the welcome which apomorphine product, will major as products a in as you more be we to for because will as drug physicians attention is

apomorphine. So, have even is delivered is hard the in a more APOKYN very about way it see And comes obviously and to what are their we product. molecule we given the forth. the excited little profile that general, to and that talk about talk a that of itself, so in bit don't APOKYN AbbVie, and the But profile about the label specifically to efficacy with

David Amsellem

around corner, just Okay. given the in a readouts I had manufacturing some the wait on to any your delay see if time, follow-up additional you would have we That's the may coming FDA approval XXX. and sneak inspections? Could helpful. also If you in want

Jack Khattar

Yeah.

the data was coming as adult. a that's as The in just up, the far pediatric. for NDA, reminder As is that only

different So, population. patient it's a

anything we because they point, readout the that haven't this at it, we heard delay have had signal a might any So, adult FDA study. on we or from haven't the

as seen we leads So heard believe at there that's haven't And because inspections, to that. anything any can any this or like the be again haven't far FDA of also say will signals or that from us manufacturing, inspections the point. what as we delay

As with on I very mentioned from finished as working earlier, or here good and before, dosage we final form product. API as CMOs call some the that even I are we the products have think earnings last side, well the the

perspective. about in So, that supplier we our feel area a very good from partners

an area could problem. However, us we again, that I be sure. to lead that I guess. know see signals that to we be a are soon, the PDUFA you very believe date, that, don't XXX% all But will very coming But we'll can close say is we haven't seen so any

David Amsellem

Jack. Thanks, Okay.

Jack Khattar

Sure.

Operator

with next Instructions] question [Operator Our you. Steinberg Thank Jefferies. David comes from

Your line is now open.

David Steinberg

had Thanks. I follow-up two just questions.

lowering one expenses the flow WorldMeds. save for $XXX late operating in around $X.XX give your behind of this secondly, in you process you and then sort first what led cash is, after to here it And or year. like paying thought million billion -- generate, in even The take cash looks have

earlier sizable best acquisition. Greg, Thanks. this of market products all -- a do for make accretion the in what's reasonably near-term And stage versus point? on of current you sort in at looking and you assets on What terms retirement. to thinking So, you could your

Gregory Patrick

David. Thanks,

Jack Khattar

everybody operating lot what even that There Yeah. to that need that or amount to predict I'll take promotion in operation its and next that first a given expenses that or done the sure able crack maybe environment, may or at the have manage certain operating the see out you never in to try expenses actually don't with of you factors prescriptions of all, play I'm difficult of are into do COVID for the the do may year. very in of fact quarter general an able that. activity mind units might a been that the remainder to extended of have the the be find and And appreciates you more you may you trends that not do environment, now because better. to happens

the was get impacted believe Clearly the to the and up of on had, will pick could It's to that has adult year. of to trial recruitment. us that have So, or for we on We've that a very don't lot R&D. lower one we pickup. Then the into obviously, finally hold, the expenses. the restart expenses how rest hard there predict operating quickly let Similarly it put trial. factors to

just not in the going we trial, R&D. and -- have adult so So much

not just there impacted next one so or delays COVID some and have trial. is activities that it's different been trials, shifting year forth. also the a of switching causing potentially by activities certain and of So, Obviously, different or multiplicity --

so also So that We expenses. estimates acquisition the forth operating that had also the program. some Navitor and impacted integration on on the WorldMeds US and

totality the for the lowering favorable, ended all operating of estimates which in this being year. So, to these expenses led up

Gregory Patrick

a acceleration between third adjustment really what recognize -- quarter. rate last see of is, discussed later math, the on said. just Jack's you'll and the a we significant from quarter. what Jack Yeah. is does expenses between down increase And is expenses the our push quarter, fourth. comments for little SG&A and the for to we in just continues still second. the the expenses third the David, projected secular a it let right if it you the then quarter what that in projecting acknowledges the in just me line, just just came the run in second in We're fourth. build third SG&A quarter exactly the fourth and year What the bit third really perhaps The into The adjustment

really That's any there favorability the a isn't guidance then the change of So, matter it. strategy. change titrating quarter thinking, year. the philosophy change or in in It's and putting the in third for just in

Jack Khattar

cash very And in regarding this position my activity as business -- activities, far continue to mentioned be I and the or second M&A as active. remarks, prepared the development as we question,

opportunities a whether a deal potential licensing, here, slowed company deal. it's haven't or whether product down in acquisitions, we at So, it's looking whether and it's

the the our putting have to So, growth. use the future same far as for intensity focus, it to utilizing as we continue drive, same same cash,

which working and will of that in we regarding are hopefully hopefully to marketplace, later And, at pump assets XX months the few the XXX -- and talked XXX get as looking two also moves at in in assets reload So other the could about the that the times so. pipeline, and assets in the are they next of on, stage. clearly and our them commercial, have key pipeline, hard point to course, moves Both we're or get pipeline. as this we're be XXX, assets addition to pretty to on,

work. are hard we at So,

at. Looking could we we're be to at other are It -- come across agnostic. also neurology. opportunities. be And our look to could It areas, it psychiatry. they they and is could opportunistic that other specialty And areas we're desk open if fairly do

Operator

questions in time. like further I closing And to to you. am remarks for Khattar I'd call no the the at showing queue Jack Thank any turn back this

Jack Khattar

one the shaping to you. be our The since XXXX years successful year most inception. of Thank up is

of We million are milestone a of sales cornerstone chapter establish $XXX looking another net the to more at space. major presence a psychiatry in and starting in growth achieving with or

many operating XX% quarters execute growth our year, employees delivered first results Our business. in areas in growth have XX% three operating year. the during continue earnings solid of a strong to compared last of well with the revenues across and to They

position commercialization in and be late-stage for potentially These by focused success. strong SPN-XXX for to market we look year. drivers the January, towards We joining important for an And them morning. the entering launch launch driving the you get us two this forward in company. of are a XXXX, and will we approval to assets very strong setting Thank and two on represent XXXX. end to Soon, and stage growth finishing XXXX exciting the SPN-XXX to in

Operator

participation conference. Ladies today's and gentlemen, your thank program. you on conclude This for your does

disconnect. now may You

Supernus Pharmaceuticals (SUPN) 4 Nov 202020 Q3 Earnings call transcript